Product Details

Vergenta is a sterile injectable formulation that meets British Pharmacopoeia (BP) standards. Specifically, it delivers Gentamicin Sulphate for use as a broad-spectrum aminoglycoside antibiotic through the intramuscular (I.M.) or intravenous (I.V.) route. As a result, it offers effective treatment against serious gram-negative bacterial infections in hospital and clinical settings.

The injection contains:

• Gentamicin Sulphate IP (equivalent to Gentamicin 80mg per 2mL) – An aminoglycoside antibiotic that binds irreversibly to the 30S ribosomal subunit of susceptible bacteria. Consequently, it disrupts protein synthesis and produces a bactericidal effect against a broad range of gram-negative organisms.

Physicians prescribe Vergenta for the treatment of serious infections caused by susceptible gram-negative bacteria, including septicaemia, urinary tract infections, respiratory tract infections, and complicated skin and soft tissue infections. In addition, its dual-route (I.M./I.V.) formulation allows flexible administration based on clinical severity. Because of this, Vergenta suits hospitals, ICUs, and clinical settings where prompt antibacterial coverage is essential.

Key Features:

• Overall, this BP-compliant formulation guarantees pharmaceutical-grade purity
• Additionally, the dual-route (I.M./I.V.) formulation offers flexible clinical use
• Furthermore, each single-use vial delivers precise, validated dosage accuracy at 80mg/2mL
• Notably, rigorous purity and sterility testing backs every stage of manufacturing
• Beyond that, light-protected vial packaging preserves product stability during storage
• Ultimately, a reliable supply chain suits bulk distribution to hospitals, clinics, and pharmacies